Christopher Marai
Stock Analyst at Nomura
(2.44)
# 2,392
Out of 4,944 analysts
33
Total ratings
51.61%
Success rate
10.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Marai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $360 → $960 | $9.59 | +9,910.43% | 2 | Jun 4, 2020 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $29 → $33 | $56.72 | -41.82% | 2 | May 11, 2020 | |
| SLDB Solid Biosciences | Maintains: Buy | $150 → $90 | $6.68 | +1,247.31% | 5 | May 8, 2020 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Reduce | $74 | $432.52 | -82.89% | 4 | Apr 14, 2020 | |
| VYGR Voyager Therapeutics | Maintains: Buy | $37 → $16 | $3.65 | +338.36% | 2 | Mar 30, 2020 | |
| BIIB Biogen | Maintains: Buy | $320 → $392 | $135.19 | +189.96% | 7 | Feb 7, 2020 | |
| BYSI BeyondSpring | Initiates: Buy | $34 | $2.02 | +1,583.17% | 1 | Jan 10, 2020 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $205 → $230 | $20.40 | +1,027.45% | 3 | Feb 28, 2019 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $22 → $12 | $13.45 | -10.78% | 3 | Dec 17, 2018 | |
| PRTA Prothena Corporation | Maintains: Buy | $87 → $19 | $8.05 | +136.02% | 2 | Apr 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $43 | $2.79 | +1,441.22% | 2 | Sep 6, 2017 |
Corbus Pharmaceuticals Holdings
Jun 4, 2020
Maintains: Buy
Price Target: $360 → $960
Current: $9.59
Upside: +9,910.43%
Protagonist Therapeutics
May 11, 2020
Maintains: Buy
Price Target: $29 → $33
Current: $56.72
Upside: -41.82%
Solid Biosciences
May 8, 2020
Maintains: Buy
Price Target: $150 → $90
Current: $6.68
Upside: +1,247.31%
Alnylam Pharmaceuticals
Apr 14, 2020
Maintains: Reduce
Price Target: $74
Current: $432.52
Upside: -82.89%
Voyager Therapeutics
Mar 30, 2020
Maintains: Buy
Price Target: $37 → $16
Current: $3.65
Upside: +338.36%
Biogen
Feb 7, 2020
Maintains: Buy
Price Target: $320 → $392
Current: $135.19
Upside: +189.96%
BeyondSpring
Jan 10, 2020
Initiates: Buy
Price Target: $34
Current: $2.02
Upside: +1,583.17%
Sarepta Therapeutics
Feb 28, 2019
Maintains: Buy
Price Target: $205 → $230
Current: $20.40
Upside: +1,027.45%
Syndax Pharmaceuticals
Dec 17, 2018
Maintains: Buy
Price Target: $22 → $12
Current: $13.45
Upside: -10.78%
Prothena Corporation
Apr 24, 2018
Maintains: Buy
Price Target: $87 → $19
Current: $8.05
Upside: +136.02%
Sep 6, 2017
Maintains: Buy
Price Target: $49 → $43
Current: $2.79
Upside: +1,441.22%